A mitochondria-related gene-based signature predicts pancreatic ductal adenocarcinoma clinical outcome and revealed CAMK2A/THEM4 regulates progression phenotypes and mitophagy in vivo and in vitro
This study establishes a mitochondria-driven prognostic model for PDAC and identifies the CAMK2A-THEM4-AKT axis as a novel therapeutic target. To our knowledge, this is the first pancreatic cancer signature that investigates the synergistic effect of candidate genes, offering both prognostic and mechanistic insights into PDAC progression.
Authors
- Zhongfei Zhu (ORCID: https://orcid.org/0000-0003-3312-1784)
- Xiaohan Shi (ORCID: https://orcid.org/0000-0003-3775-3076)
- Gang Jin (ORCID: https://orcid.org/0000-0001-6713-1185)
- Gang Li (ORCID: https://orcid.org/0000-0002-8080-4134)
- Jing Huang (ORCID: https://orcid.org/0000-0002-9607-7250)
- Gang Nie (ORCID: https://orcid.org/0000-0003-3667-6603)
- Xiaoyi Yin (ORCID: https://orcid.org/0000-0003-4154-2044)
Institutions
- Second Military Medical University (CN)
- Changhai Hospital (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-12-06
- DOI
- https://doi.org/10.1186/s12967-025-07456-5
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00